CU20180127A7 - Composiciones inmunogénicas de chagas - Google Patents

Composiciones inmunogénicas de chagas

Info

Publication number
CU20180127A7
CU20180127A7 CU2018000127A CU20180127A CU20180127A7 CU 20180127 A7 CU20180127 A7 CU 20180127A7 CU 2018000127 A CU2018000127 A CU 2018000127A CU 20180127 A CU20180127 A CU 20180127A CU 20180127 A7 CU20180127 A7 CU 20180127A7
Authority
CU
Cuba
Prior art keywords
immunogenic compositions
chagas
trypanosome
antigens
medications
Prior art date
Application number
CU2018000127A
Other languages
English (en)
Inventor
Wilson Romero Caparros-Wanderley
Mateo Olga Pleguezuelos
Gregory Alan Stoloff
Original Assignee
Peptcell Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptcell Ltd filed Critical Peptcell Ltd
Publication of CU20180127A7 publication Critical patent/CU20180127A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/005—Trypanosoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

<p>La presente memoria descriptiva describe antígenos de tripanosoma, composiciones inmunogénicas y medicamentos que comprenden los antígenos de tripanosoma, métodos y usos para los antígenos de tripanosoma y composiciones inmunogénicas para el tratamiento contra una enfermedad basada en tripanosoma.</p>
CU2018000127A 2016-04-14 2017-04-18 Composiciones inmunogénicas de chagas CU20180127A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662322770P 2016-04-14 2016-04-14
PCT/EP2017/059189 WO2017178660A1 (en) 2016-04-14 2017-04-18 Chagas antigens and antibodies and compositions, methods and uses thereof

Publications (1)

Publication Number Publication Date
CU20180127A7 true CU20180127A7 (es) 2019-08-06

Family

ID=58671580

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2018000127A CU20180127A7 (es) 2016-04-14 2017-04-18 Composiciones inmunogénicas de chagas

Country Status (18)

Country Link
US (2) US10973897B2 (es)
EP (1) EP3442569A1 (es)
JP (1) JP2019513797A (es)
KR (1) KR20190039022A (es)
CN (2) CN116059330A (es)
AU (1) AU2017248680A1 (es)
BR (1) BR112018071108A2 (es)
CA (1) CA3020856A1 (es)
CL (2) CL2018002932A1 (es)
CO (1) CO2018012295A2 (es)
CU (1) CU20180127A7 (es)
EC (1) ECSP18079073A (es)
MX (1) MX2018012504A (es)
NI (1) NI201800105A (es)
PE (1) PE20190104A1 (es)
RU (1) RU2018139865A (es)
SG (1) SG11201808915YA (es)
WO (1) WO2017178660A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2594637B (en) * 2019-01-07 2023-08-02 Genome Res Ltd Novel trypanosomal vaccine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2731370A1 (de) * 1977-07-12 1979-01-25 Behringwerke Ag Chagas impfstoff und verfahren zu dessen herstellung
ES2169995B1 (es) 2000-04-17 2003-12-01 Leti Lab Composicion a base de la proteina lip2a y su uso en la preparacion de un medicamento para suscitar una respuesta inmune contra un antigeno.
US20040057958A1 (en) 2002-05-17 2004-03-25 Waggoner David W. Immunogenicity-enhancing carriers and compositions thereof and methods of using the same
SA110310855B1 (ar) * 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي
US9804158B2 (en) 2013-07-02 2017-10-31 Institut De Recherche Pour Le Développement Peptides and methods for the detection of Leishmaniasis
US9566320B2 (en) 2013-09-24 2017-02-14 The Board Of Regents Of The University Of Texas System Mucin-associated surface protein as vaccine against Chagas disease

Also Published As

Publication number Publication date
CN116059330A (zh) 2023-05-05
AU2017248680A1 (en) 2018-11-22
ECSP18079073A (es) 2019-02-28
EP3442569A1 (en) 2019-02-20
WO2017178660A1 (en) 2017-10-19
CN109310747A (zh) 2019-02-05
CL2021001441A1 (es) 2021-11-19
MX2018012504A (es) 2019-08-29
CA3020856A1 (en) 2017-10-19
JP2019513797A (ja) 2019-05-30
PE20190104A1 (es) 2019-01-15
BR112018071108A2 (pt) 2019-02-26
WO2017178660A9 (en) 2017-12-07
US20210220453A1 (en) 2021-07-22
SG11201808915YA (en) 2018-11-29
NI201800105A (es) 2019-02-18
US10973897B2 (en) 2021-04-13
US20170296637A1 (en) 2017-10-19
CL2018002932A1 (es) 2019-02-01
KR20190039022A (ko) 2019-04-10
CN109310747B (zh) 2022-11-22
CO2018012295A2 (es) 2019-04-30
RU2018139865A (ru) 2020-05-14

Similar Documents

Publication Publication Date Title
CL2018001230A1 (es) Tratamiento de osteoartritis
AR102657A1 (es) Composición para tratar telas
CL2017002786A1 (es) Referencia cruzada a solicitudes relacionadas
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
CL2017003151A1 (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas
CL2018002692A1 (es) Vacuna bivalente contra el virus de gripe porcina.(divisional solicitud 201701961)
CL2016002044A1 (es) Inserto de codificación para usar en una máquina de preparación de alimentos.
CL2017000715A1 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo
AR104664A1 (es) Conjugados de fármacos con anticuerpos contra la cadherina 6 (anti-cdh6)
BR102015017380A2 (pt) dispositivo para a reticulação do tecido do olho, e, composição farmacêutica
CO2017005038A2 (es) Composicones y métodos de tratamiento con profármacos de tizoxanida, un análogo o sal de la misma
MX2020004543A (es) Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan.
CL2016001756A1 (es) Preparación farmacéutica que comprende 0,001-0,003 pv de 6-4-pirazol-1-ilbencilpiridin-3-ilsulfonilaminometilpiridin-2-ilaminoacetato de isopropilo o una sal del mismo uso para el tratamiento o prevención de glaucoma o hipertensión ocular.
CL2017001539A1 (es) Compuestos indenil, composiciones farmacéuticas y sus usos médicos de los mismos
CO6551750A2 (es) Vacuna del virus del dengue inactivado que incluye un adyuvante sin aluminio
CL2016002338A1 (es) Uso de un compuesto que es ácido r-2-4-2-etoxi-3-4-trifluorometilfenoxipropil-tio-2-metilfenoxi acético, para el tratamiento de una enfermedad colestásica intrahepática .
BR112019003992A2 (pt) vacina contra neisseria meningitidis
CO2017000950A2 (es) Compuestos que comprenden oligonucleótidos modificados dirigidos a mir-103 y/o mir-107 para trastornos metabólicos
BR112016028316A2 (pt) composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamento
CL2019001522A1 (es) Oligonucleótidos modificados para el tratamiento de una enfermedad poliquística renal.
CO2018013828A2 (es) Composiciones farmacéuticas de oligómero de morfolino fósforodiamidato
CL2016002779A1 (es) Composición para el cuidado de la piel
CL2018000513A1 (es) Vacunas de pestivirus para temblores congénitos
PE20160596A1 (es) Formulacion de atazanavir y cobicistat para el tratamiento del virus de inmunodeficiencia humana
CL2016002267A1 (es) Ureas asimétricas p-sustituidas y usos médicos de las mismas